BIIB
About BIIB
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Company Information
Biogen Analysts Lower Their Forecasts After Q4 Results
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Biogen Inc. (BIIB) Q1 Earnings Lag Estimates
Macro Factor Sensitivities
Technical Analysis
Based on technical indicators and chart patterns, BIIB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...